Get started
Award

Optimization of Blood Biomarker Use in AD Clinical Trials

Description: How do certain blood-based proteins impact the risk and progression of Alzheimer’s in different individuals?
Funding type: research
Funder scheme: AARF
Start date: 2023-01-01
Investigator: Marta Mila Aloma
Institution: Northern California Institute for Research and Education
Funded outputs count: 7
Funder award ID: AARF-23-1141384
OpenAlex ID: G7537029828
Detecting early memory changes in preclinical Alzheimer's disease using TabCAT favorites test: Data from the European Prevention of Alzheimer's Disease (EPAD) cohort
2026 · Anna Brugulat‐Serrat, Elena Tsoy, et al. · Alzheimer s & Dementia
PDF
Sex differences in Alzheimer's disease plasma biomarker levels and clinical utility
2026 · Marta Milà‐Alomà, Isabella Hausle, et al. · Alzheimer s & Dementia · 2
Plasma p-tau212 identifies cognitively unimpaired individuals with emerging amyloid-β pathology
2025 · Przemysław R. Kac, Armand González-Escalante, et al. · Journal of Neurology · 3
PDF
Sex differences in Alzheimer’s disease CSF biomarkers and their association with Aβ pathology on PET in cognitively unimpaired individuals
2025 · Marta Milà-Alomà, Carol Van Hulle, et al. · Alzheimer s Research & Therapy · 7
PDF
Temporal sequence of amyloid and tau PET positivity: APOE -ε4 and sex effects, and implications for Alzheimer’s disease progression
2025 · Marta Milà-Alomà, Isabella Hausle, et al. · medRxiv · 1
PDF
Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET Clocks
2025 · Marta Milà‐Alomà, Duygu Tosun, et al. · Annals of Neurology · 41
PDF
A plasma biomarker panel for detecting early amyloid-β accumulation and its changes in middle-aged cognitively unimpaired individuals at risk for Alzheimer’s disease
2025 · Armand González-Escalante, Marta Milà-Alomà, et al. · EBioMedicine · 22
PDF
Year
Topic